Liu Y, Gong L, Feng J, Xiao C, Liu C, Chen B
J Nanobiotechnology. 2025; 23(1):194.
PMID: 40059141
PMC: 11892300.
DOI: 10.1186/s12951-025-03170-y.
Piao W, Wu L, Xiong Y, Zapas G, Paluskievicz C, Oakes R
Nat Commun. 2024; 15(1):10468.
PMID: 39622857
PMC: 11612289.
DOI: 10.1038/s41467-024-54874-y.
Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C
Exp Hematol Oncol. 2024; 13(1):80.
PMID: 39107856
PMC: 11301948.
DOI: 10.1186/s40164-024-00543-1.
Zou Z, Shen J, Xue D, Li H, Xu L, Cao W
Nat Commun. 2024; 15(1):4701.
PMID: 38830882
PMC: 11148143.
DOI: 10.1038/s41467-024-49034-1.
Xue J, Chen X, An X, Wang J, Zang M, Mao B
PLoS One. 2024; 19(5):e0303171.
PMID: 38768113
PMC: 11104603.
DOI: 10.1371/journal.pone.0303171.
IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype.
Wang L, Wei Y, Jin Z, Liu F, Li X, Zhang X
Clin Exp Med. 2024; 24(1):102.
PMID: 38758367
PMC: 11101573.
DOI: 10.1007/s10238-024-01328-w.
Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y, Wu Y, Yan G, Zhang G
Front Immunol. 2024; 15:1369626.
PMID: 38690273
PMC: 11058640.
DOI: 10.3389/fimmu.2024.1369626.
An AI-based approach for modeling the synergy between radiotherapy and immunotherapy.
Peng H, Moore C, Zhang Y, Saha D, Jiang S, Timmerman R
Sci Rep. 2024; 14(1):8250.
PMID: 38589494
PMC: 11001871.
DOI: 10.1038/s41598-024-58684-6.
The current status and future of PD-L1 in liver cancer.
Hao L, Li S, Deng J, Li N, Yu F, Jiang Z
Front Immunol. 2023; 14:1323581.
PMID: 38155974
PMC: 10754529.
DOI: 10.3389/fimmu.2023.1323581.
Establishment of a Seven-Gene Signature Associated with CD8 T Cells through the Utilization of Both Single-Cell and Bulk RNA-Sequencing Techniques in Clear Cell Renal Cell Carcinoma.
Chen Y, Zhou X, Xie Y, Wu J, Li T, Yu T
Int J Mol Sci. 2023; 24(18).
PMID: 37762031
PMC: 10530336.
DOI: 10.3390/ijms241813729.
LIGHTing CAR T in the tumor microenvironment.
Liang Y, Fu Y
Mol Ther. 2023; 31(9):2570-2571.
PMID: 37607540
PMC: 10492016.
DOI: 10.1016/j.ymthe.2023.08.006.
Ncoa2 Promotes CD8+ T cell-Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function.
Zhong X, Wu H, Ouyang C, Zhang W, Shi Y, Wang Y
Cancer Immunol Res. 2023; 11(10):1414-1431.
PMID: 37540802
PMC: 10592187.
DOI: 10.1158/2326-6066.CIR-23-0092.
Polymer/copper nanocomplex-induced lysosomal cell death promotes tumor lymphocyte infiltration and synergizes anti-PD-L1 immunotherapy for triple-negative breast cancer.
Hu X, Wang M, Shi S, Keerthi Raja M, Gupta G, Chen H
Biomater Sci. 2023; 11(16):5641-5652.
PMID: 37409576
PMC: 10530473.
DOI: 10.1039/d3bm00627a.
PD-1 inhibitors-based second-line therapy for metastatic gastric cancer.
Gou M, Zhang Y, Wang Z, Dai G
Front Immunol. 2023; 14:1136437.
PMID: 37304303
PMC: 10251434.
DOI: 10.3389/fimmu.2023.1136437.
A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy.
Zhou Z, Van der Jeught K, Li Y, Sharma S, Yu T, Moulana I
Adv Sci (Weinh). 2023; 10(23):e2300548.
PMID: 37271874
PMC: 10427404.
DOI: 10.1002/advs.202300548.
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.
Wang-Bishop L, Kimmel B, Ngwa V, Madden M, Baljon J, Florian D
Sci Immunol. 2023; 8(83):eadd1153.
PMID: 37146128
PMC: 10226150.
DOI: 10.1126/sciimmunol.add1153.
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy.
Wang Y, Zhou S, Wang Y, Lu Z, Zhang Y, Xu C
Nat Commun. 2023; 14(1):1993.
PMID: 37031188
PMC: 10082825.
DOI: 10.1038/s41467-023-37656-w.
NLRC3 is a potential prognostic biomarker that is correlated with immune cell infiltration in lung adenocarcinoma.
Zhuo Y, Li X, Feng W
Sci Rep. 2023; 13(1):2923.
PMID: 36808166
PMC: 9941471.
DOI: 10.1038/s41598-022-23979-z.
Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma.
Jia M, Liu C, Liu Y, Bao Z, Jiang Y, Sun X
J Pers Med. 2023; 13(1).
PMID: 36675674
PMC: 9866779.
DOI: 10.3390/jpm13010013.
Theranostics for Triple-Negative Breast Cancer.
Choi H, Kim K
Diagnostics (Basel). 2023; 13(2).
PMID: 36673082
PMC: 9857659.
DOI: 10.3390/diagnostics13020272.
